6-Amino-4-chlor-5-nitro-2-phenyl-pyrimidin | 21164-34-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 6-Amino-4-chlor-5-nitro-2-phenyl-pyrimidin
• 英文别名: 6-Chloro-5-nitro-2-phenyl-pyrimidin-4-ylamine；6-chloro-5-nitro-2-phenylpyrimidin-4-amine
• CAS: 21164-34-1
• 化学式: C₁₀H₇ClN₄O₂
• 分子量: 250.644
• InChiKey: GKMKJQWLJPZKMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-Amino-4-chlor-5-nitro-2-phenyl-pyrimidin 在 palladium 10% on activated carbon 氢气 、 三乙胺 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 2.0h， 以64%的产率得到2-苯基嘧啶-4,5-二胺
  参考文献：
  名称：

  [EN] NOVEL BENZIMIDAZOLE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE

  摘要：

  公开号：

  WO2004002986A3

文献信息

• Heterocyclic Amplifiers of Phleomycin. VI. Some Phenylpurines, Phenylpteridines, Phenylquinazolines and Related Compounds
  作者：DJ Brown、K Mori

  DOI：10.1071/ch9850467

  日期：——

  Synthetic routes are described to a series of 2-, 6- and 8- phenylpurines , each with an appropriate S-or NH-linked side chain elsewhere in the molecule; to 2- and 4-phenylpteridines, each with a similar side chain and some with two additional C-methyl groups, to 2- and 4-phenylquinazolines, each equipped with an analogous side chain; and to two pyridinyl analogues of the above. Three of the above components are shown to have considerable activity as amplifiers of phleomycin -G in an in vitro bacterial system.

  本研究描述了一系列 2-、6-和 8-苯基嘌呤的合成路线，每种嘌呤在分子的其他部位都有适当的 S 或 NH 链接侧链；2-和 4-苯基蝶啶，每种蝶啶都有类似的侧链，有些蝶啶还带有两个额外的 C-甲基；2-和 4-苯基喹唑啉，每种喹唑啉都带有类似的侧链；以及上述喹唑啉的两种吡啶类似物。在体外细菌系统中，上述成分中的三种被证明具有相当高的活性，可作为 phleomycin -G 的扩增剂。
• Novel benzimidazole derivatives
  申请人：Otake Norikazu

  公开号：US20060205750A1

  公开（公告）日：2006-09-14

  The present invention relates to a compound of the formula (I): (wherein A, B , C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO 2 R 4 )—, —N(COR 5 )— or —CO—; Y is —C(R 6 )(R 7 )—, —O— or —N(R 8 )—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.

  本发明涉及一种式(I)的化合物：其中A、B、C和D分别独立表示氮或可选取代的甲烷基；E表示氮、甲烷基或羟基取代的甲烷基；n为0或1；T、U、V和W分别独立表示氮或可选取代的甲烷基；X为—N（SO2R4）—、—N（COR5）—或—CO—；Y为—C（R6）（R7）—、—O—或—N（R8）—，但当化合物（I）中E为氮，n为0，X为—CO—，Y为—O—时，该化合物被排除在外。此外，该化合物及其类似物可用作治疗与NPY相关的各种疾病的药物，例如心血管疾病如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛、动脉硬化等；中枢神经系统疾病如贪食症、抑郁症、焦虑症、癫痫、痴呆、疼痛、酗酒、戒断症状、生物钟紊乱、精神分裂症、记忆力减退、睡眠障碍、认知障碍等；代谢性疾病如肥胖症、糖尿病、激素异常、高胆固醇血症、高脂血症、痛风、脂肪肝等；生殖系统疾病如不孕症、早产、性功能障碍等；胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等；例如动脉粥样硬化、性腺功能减退、高雄激素血症、多囊卵巢综合症（皮克威克综合症）、多毛症、胃肠道运动障碍、肥胖相关的胃食管反流、肥胖低通气综合症、睡眠呼吸暂停、炎症、血管系统全身性炎症、骨关节炎、胰岛素抵抗、支气管收缩、酒精偏好、代谢综合症、阿尔茨海默病、心脏肥大、左心室肥大、高三酰甘油血症、低高密度脂蛋白胆固醇、心血管疾病如冠心病、脑血管疾病、中风、周围血管疾病、猝死、胆囊疾病、癌症（乳腺、子宫内膜、结肠）、呼吸困难、高尿酸血症、生育能力下降、腰痛或麻醉风险增加等。
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：OTAKE NORIKAZU

  公开号：US20100048600A1

  公开（公告）日：2010-02-25

  The present invention relates to a compound of the formula (I): (wherein A, B , C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO 2 R 4 )—, —N(COR 5 )— or —CO—; Y is —C(R 6 )(R 7 )—, —O— or —N(R 8 )—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.

  本发明涉及一种式（I）的化合物：其中A、B、C和D独立地表示氮或可选取代的亚甲基；E表示氮、亚甲基或羟基取代的亚甲基；n为0或1；T、U、V和W独立地表示氮或可选取代的亚甲基；X为-N（SO2R4）-、-N（COR5）-或-CO-；Y为-C（R6）（R7）-、-O-或-N（R8）-，但当E为氮，n为0，X为-CO-，且Y为-O-时，化合物（I）被排除。此类化合物可用作治疗与NPY相关的各种疾病的药物，例如心血管疾病（如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛、动脉硬化等）、中枢神经系统疾病（如暴食症、抑郁症、焦虑症、癫痫、老年痴呆、疼痛、酗酒、戒毒、昼夜节律紊乱、精神分裂症、记忆障碍、睡眠障碍、认知障碍等）、代谢性疾病（如肥胖症、糖尿病、激素异常、高胆固醇血症、高脂血症、痛风、脂肪肝等）、生殖系统或生殖障碍（如不孕症、早产、性功能障碍等）、胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等，例如动脉粥样硬化、性腺功能减退、高雄激素症、多囊卵巢综合征（匹克威克综合征）、多毛症、胃肠道运动障碍、肥胖相关胃食管反流、肥胖低通气综合征、睡眠呼吸暂停、炎症、血管系统全身性炎症、骨关节炎、胰岛素抵抗、支气管收缩、酒精偏好、代谢综合征、阿尔茨海默病、心脏肥大、左心室肥大、高三酰甘油血症、低高密度脂蛋白胆固醇、心血管疾病如冠心病、脑血管疾病、中风、外周血管疾病、猝死、胆囊疾病、癌症（乳腺、子宫内膜、结肠）、气短、高尿酸血症、生育能力受损、腰痛或麻醉风险增加等。
• BROWN, D. J.;MORI, KENYA, AUSTRAL. J. CHEM., 1985, 38, N 3, 467-474
  作者：BROWN, D. J.、MORI, KENYA

  DOI：——

  日期：——
• US7105526B2
  申请人：——

  公开号：US7105526B2

  公开（公告）日：2006-09-12